Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,616 across all filing types
Latest filing 2023-06-15 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
关于股东部分股份解押及质押的公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding the partial release and re-pledge of shares by its controlling shareholder, Haiwang Group. It details the number of shares involved, pledge ratios, pledge purposes, and related financial data of the controlling shareholder. The content focuses on share pledge and release activities, which are related to capital structure and financing activities. There is no indication that this is a full financial report, earnings release, or management discussion. The document length is about 3,081 characters, which is relatively short and typical for a capital/financing update announcement. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2023-06-15 Chinese
2022年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a "2022 Annual General Meeting Resolution Announcement" for Shenzhen Haier Bioengineering Co., Ltd. It details the date and method of the meeting, attendance, voting results on various proposals including the 2022 annual report, financial statements, profit distribution plan, and appointment of auditors. The document includes detailed voting results and legal opinions confirming the validity of the meeting and resolutions. The content is focused on the announcement of the voting results and resolutions passed at the Annual General Meeting (AGM). It does not contain the full annual report or financial statements themselves, but rather the official results of shareholder votes on these matters. Therefore, this document fits the category of "Declaration of Voting Results & Voting Rights Announcements" (DVA). The document length is about 5,056 characters, which is sufficient for a detailed voting result announcement rather than a brief report publication announcement. Hence, the classification is DVA with high confidence.
2023-05-29 Chinese
北京德恒（深圳）律师事务所关于深圳市海王生物股份有限公司2022年度股东大会的法律意见
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the 2022 Annual General Meeting (AGM) of Shenzhen Haiwang Bioengineering Co., Ltd. It details the legality of the meeting's convening, attendance, voting procedures, and results. The document includes specific voting results on various agenda items from the AGM. It does not contain the full annual report or financial statements but rather focuses on the legal validation of the AGM process and resolutions. This type of document is typically classified as Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting outcomes and confirms the legitimacy of the AGM proceedings.
2023-05-29 Chinese
关于筹划重大事项的进展公告
Capital/Financing Update Classification · 95% confidence The document is a progress announcement regarding a major transaction or significant corporate event. It references previous announcements about planning major matters and states that no formal agreement has been signed yet. It discusses ongoing negotiations, audit and evaluation work, and future steps including signing agreements and fulfilling disclosure obligations. The document is relatively short (1727 characters) and serves as an update on the progress of a major matter rather than a full report or financial statement. It does not contain financial statements or detailed financial data, nor is it a certification or voting result. The content aligns with announcements about capital or financing activities or major corporate transactions in progress. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2023-05-28 Chinese
关于对深圳证券交易所2022年年报问询函回复的公告
Annual Report Classification · 95% confidence The document is a detailed response from Shenzhen Haiwang Bioengineering Co., Ltd. to an inquiry letter from the Shenzhen Stock Exchange regarding the company's 2022 annual report. It includes extensive financial data, specifically about goodwill impairment testing, detailed tables of subsidiary financials, assumptions and methodologies used in impairment testing, and references to the 2022 fiscal year. The document is lengthy (15,000 characters) and contains substantive financial data and analysis related to the annual report. It is not merely an announcement or a certification but a detailed management response with financial details. Therefore, this document is best classified as an Annual Report (10-K) or a closely related detailed financial report. Given the context and the nature of the content focusing on the annual report and its financial details, the classification is Annual Report (10-K). FY 2022
2023-05-19 Chinese
关于对深圳市海王生物工程股份有限公司2022年年报问询函中要求会计师发表意见有关问题的专项说明
Audit Report / Information Classification · 95% confidence The document is a detailed explanation and response related to the 2022 annual report (年报) of Shenzhen Haier Bioengineering Co., Ltd. It discusses the auditor's opinion on goodwill impairment, including detailed financial data, audit procedures, assumptions, and key parameters used in impairment testing. The presence of extensive financial tables, audit references, and discussion of accounting standards indicates this is a standalone audit report or audit-related information rather than the full annual report itself. The document is not a brief announcement or a certification letter but contains substantive audit analysis and results. Therefore, it fits best under the category 'Audit Report / Information' (AR). FY 2022
2023-05-19 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.